Semiquantitative fecal calprotectin test in postinfectious and non-postinfectious irritable bowel syndrome
cross-sectional study
Keywords:
Leukocyte L1 antigen complex, Inflammation, Inflammatory bowel diseases, Irritable bowel syndrome, GastroenteritisAbstract
CONTEXT AND OBJECTIVE: The presence of a certain degree of inflammation in the gut wall is now ac-cepted in irritable bowel syndrome (IBS). Fecal calprotectin is considered to be a reliable test for detecting intestinal inflammation. Our aim was to assess the presence of inflammation in postinfectious IBS (PI-IBS), compared with non-postinfectious IBS (NPI-IBS). A secondary objective was to determine the usefulness of a rapid fecal calprotectin test in inflammatory bowel diseases (IBD). DESIGN AND SETTING: This was a cross-sectional study. Patients with IBS and IBD at a single tertiary gastroenterology center were prospectively included in this study. METHODS: 116 patients with Rome III IBS score (76 females; 48 ± 12 years) were investigated; 24 patients (15 females) had PI-IBS. Intestinal inflammation was assessed using the semiquantitative fecal calprotec-tin test. The results were expressed as T1, T2 or T3 according to the severity of inflammation (< 15 µg/g; 15-60 µg/g; > 60 µg/g). Using the same test, we evaluated 20 patients with IBD (12 males; 47 ± 13 years). RESULTS: None of the patients with IBS had a T2 or T3 positive test. Among PI-IBS patients, 33% had a T1 positive test. Among NPI-IBS patients, 9.8% had a T1 positive test, which was significantly different to PI-IBS. The calprotectin test was positive in all IBD patients: 80% with T3, 10% with T2 and 10% with T1. CONCLUSIONS: Using a semiquantitative test for fecal calprotectin, positive tests were more frequent in PI-IBS patients than in NPI-IBS patients.
Downloads
References
Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology. 2006;130(5):1480-91.
Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 2000;119(1):15-22.
Shastri Y, Povse N, Stein J. A prospective comparative study for new rapid bedside fecal calprotectin test with an established ELISA to assess intestinal inflammation. Clin Lab. 2009;55(1-2):53-5.
Saverymuttu SH. Clinical remission in Crohn’s disease--assessment using faecal 111In granulocyte excretion. Digestion. 1986;33(2):74-9.
Sipponen T, Kolho KL. Faecal calprotectin in children with clinically quiescent inflammatory bowel disease. Scand J Gastroenterol. 2010;45(7-8):872-7.
Sipponen T, Savilahti E, Kärkkäinen P, et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn’s disease. Inflamm Bowel Dis. 2008;14(10):1392-8.
Sipponen T, Björkesten CG, Färkkilä M, et al. Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn’s disease treatment. Scand J Gastroenterol. 2010;45(3):325-31.
Tibble JA, Sigthorsson G, Foster R, Forgacs I, Bjarnason I. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology. 2002;123(2):450-60.
Sydora MJ, Sydora BC, Fedorak RN. Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome. J Crohns Colitis. 2012;6(2):207-14.
Burri E, Beglinger C. Faecal calprotectin -- a useful tool in the management of inflammatory bowel disease. Swiss Med Wkly. 2012;142:w13557.
Parry S, Forgacs I. Intestinal infection and irritable bowel syndrome. Eur J Gastroenterol Hepatol. 2005;17(1):5-9.
Zanini B, Ricci C, Bandera F, et al. Incidence of post-infectious irritable bowel syndrome and functional intestinal disorders following a water-borne viral gastroenteritis outbreak. Am J Gastroenterol. 2012;107(6):891-9.
Bjarnason I, Hayllar J, MacPherson AJ, Russell AS. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology. 1993;104(6):1832-47.
Bjarnason I, MacPherson A, Hollander D. Intestinal permeability: an overview. Gastroenterology. 1995;108(5):1566-81.
Fagerberg UL, Lööf L, Merzoug RD, Hansson LO, Finkel Y. Fecal calprotectin levels in healthy children studied with an improved assay. J Pediatr Gastroenterol Nutr. 2003;37(4):468-72.
Røseth AG, Kristinsson J, Fagerhol MK, et al. Faecal calprotectin: a novel test for the diagnosis of colorectal cancer? Scand J Gastroenterol. 1993;28(12):1073-6.
Vestergaard TA, Nielsen SL, Dahlerup JF, Hornung N. Fecal calprotectin: assessment of a rapid test. Scand J Clin Lab Invest. 2008;68(4):343-7.
Sofar. Cal Detect. Available from: http://www.sofar.ro/sisteme-diagnosticare/cal-detect.html. Accessed in 2014 (Aug 15).
Dranga M, Dumitrescu G, Badea M, et al. The semi-quantitative calprotectin rapid test--is it useful in inflammatory bowel disease? Rev Med Chir Soc Med Nat Iasi. 2012;116(3):761-5.
Neal KR, Hebden J, Spiller R. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. BMJ. 1997;314(7083):779-82.
Tursi A, Brandimarte G, Elisei W, et al. Faecal calprotectin in colonic diverticular disease: a case-control study. Int J Colorectal Dis. 2009;24(1):49-55.
Schröder O, Naumann M, Shastri Y, Povse N, Stein J. Prospective evaluation of faecal neutrophil-derived proteins in identifying intestinal inflammation: combination of parameters does not improve diagnostic accuracy of calprotectin. Aliment Pharmacol Ther. 2007;26(7):1035-42.
Spiller RC, Jenkins D, Thornley JP, et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut. 2000;47(6):804-11.
Chaudhary NA, Truelove SC. The irritable colon syndrome. A study of the clinical features, predisposing causes, and prognosis in 130 cases. Q J Med. 1962;31:307-22.
Dunlop SP, Jenkins D, Neal KR, Spiller RC. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology. 2003;125(6):1651-9.
Dunlop SP, Jenkins D, Spiller RC. Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome. Am J Gastroenterol. 2003;98(7):1578-83.
von Roon AC, Karamountzos L, Purkayastha S, et al. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol. 2007;102(4):803-13.
Hämäläinen A, Sipponen T, Kolho KL. Infliximab in pediatric inflammatory bowel disease rapidly decreases fecal calprotectin levels. World J Gastroenterol. 2011;17(47):5166-71.
Meling TR, Aabakken L, Røseth A, Osnes M. Faecal calprotectin shedding after short-term treatment with non-steroidal anti-inflammatory drugs. Scand J Gastroenterol. 1996;31(4):339-44.
García Sánchez Mdel V, González R, Iglesias Flores E, et al. Precisión diagnóstica de la calprotectina fecal para predecir una colonoscopia patológica [Diagnostic value of fecal calprotectin in predicting an abnormal colonoscopy]. Med Clin (Barc). 2006;127(2):41-6.
Husebye E, Tøn H, Johne B. Biological variability of fecal calprotectin in patients referred for colonoscopy without colonic inflammation or neoplasm. Am J Gastroenterol. 2001;96(9):2683-7.
Grad C, David L, Portincasa P, Dumitrascu DL. Diagnostic value of calprotectin in irritable bowel syndrome and in inflammatory bowel disease. Rom J Intern Med. 2012;50(1):3-6.
